CD8A and breast neoplasm: Nonetheless, these data suggest that targeting DNMT1 in breast tumors can upregulate MHC-I mediated antigen presentation and tip the balance at equilibrium to elicit a CD8+ T cell response which promotes tumor regression and anti-tumor immunity.